About BioSimulytics
BioSimulytics is a company based in Dublin (Ireland) founded in 2019 by Peter F Doyle, Niall English, and Christian Burnham. BioSimulytics has raised $709.43 thousand across 3 funding rounds from investors including University College Dublin, Enterprise Ireland and EIC Fund. BioSimulytics operates in a competitive market with competitors including Zephyr AI, Precisionlife, Chemify, Transaction Data Systems and RevolKa, among others.
- Headquarter Dublin, Ireland
- Founders Peter F Doyle, Niall English, Christian Burnham
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$709.43 K (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
University College Dublin
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of BioSimulytics
BioSimulytics has successfully raised a total of $709.43K across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioSimulytics
BioSimulytics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include University College Dublin, Enterprise Ireland and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Support is provided to Irish manufacturing and service sector businesses.
|
Locked | Locked | Locked | |
|
Multiple courses and degrees across diversified streams are offered.
|
Locked | Locked | Locked |
Investor details for BioSimulytics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioSimulytics
Investment portfolio details for BioSimulytics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioSimulytics
Detailed financials for BioSimulytics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biosimulytics Comparisons
Peer comparison for BioSimulytics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioSimulytics
BioSimulytics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zephyr AI, Precisionlife, Chemify, Transaction Data Systems and RevolKa, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI development services for biopharma sector
|
|
| Locked | Locked | Locked |
AI-enabled platforms for drug discovery and precision medicine are developed.
|
|
| Locked | Locked | Locked |
Software development services are provided for pharmaceutical and materials research.
|
|
| Locked | Locked | Locked |
Software development services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
AI development services are provided for the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery and design are enabled by a cloud-based platform.
|
Detailed competitors of BioSimulytics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biosimulytics
Complete news archive for BioSimulytics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioSimulytics
BioSimulytics was founded in 2019.
BioSimulytics is headquartered in Dublin, Ireland.
Peter F Doyle is the current CEO of BioSimulytics. They have also founded this company.
BioSimulytics is a funded company, having raised a total of $709.43K across 3 funding rounds to date.
BioSimulytics was founded in 2019 and is headquartered in Dublin, Ireland. Operations focus on the biopharma sector, where an AI-enhanced platform for molecular modelling is developed and provided. Services support drug discovery and simulation processes through computational tools. The company is led by co-founders including Peter F Doyle as CEO, Niall English, and Christian Burnham. Activities are centered on advancing predictive analytics in biotechnology.
BioSimulytics has 3 investors. Key investors include University College Dublin, Enterprise Ireland, and EIC Fund.